Post Reply
1-3 of 3
SDAI to Launch its Proprietary Plant Stem Cells Skincare in Singapore and China as Part of Strategic Transformation into a Biotechnology Company
SINGAPORE, 10 December 2025 &ndash The board of directors (the &ldquo Board&rdquo ) of SDAI Limited (the &ldquo Company&rdquo or &ldquo SDAI&rdquo , and together with its subsidiaries, the &ldquo Group&rdquo ) is pleased to announce that the official launch of its proprietary skincare line, the Bluecode Biotech B-III skincare series (蓝 码 生 物 B-III 系 列 ) (&ldquo B-III Series&rdquo ), will take place on 21 December 2025. This debut marks a significant milestone in SDAI&rsquo s transformation journey as the Group advances into the fast-growing anti-aging and biotechnology sectors, underscoring its commitment to innovation and long-term growth.
The B-III Series will debut simultaneously in Singapore and China. In Singapore, the first product to be introduced is the Photoprotective Bio Facial Mist (抗 光 损 喷 雾 ). In China, three products will be launched concurrently: (i) the Apple Fruit Cell Serum (苹 果 果 实 细 胞 精 华 液 ), (ii) the Photoprotective Bio Facial Mist, and (iii) the Adenium Obesum Cell Facial Mask (沙 漠 蔷 薇 叶 细 胞 面 膜 ). The new products will be distributed primarily through established e-commerce platforms to maximise market reach and enhance consumer accessibility.
Revolutionising Plant Stem-Cell Skincare with Advanced Bioengineering
Developed by the Group&rsquo s in-house R& D team, the B-III Series is crafted to unlock the regenerative power of nature through cellular rejuvenation. Daily exposure to environmental stressors and modern lifestyle habits can disrupt the skin&rsquo s natural cell-to cell communication, leading to visible signs of aging including wrinkles, dullness, dehydration, loss of elasticity, and lingering scars.
Compounded by common skincare misconceptions and excessive treatments that weaken the skin barrier, premature aging becomes increasingly difficult to reverse. Under the Bluecode Biotech B-III brand, the Group redefines skincare by introducing a breakthrough approach that restores the skin&rsquo s internal communication pathways and activates its natural self-repair ability (&ldquo 激 发 肌 肤 细 胞 自 愈 力 &rdquo ).
Harnessing next-generation bioengineering and advanced plant stem-cell technology, the B-III Series rejuvenates the skin&rsquo s cellular network, enhancing balance, resilience, and youthful radiance from within. Instead of addressing concerns only at the surface level, B-III targets the root causes of cellular aging, empowering the skin to renew, rebuild and restore itself naturally.
https://links.sgx.com/FileOpen/SDAI%20-%20Launch%20of%20B-III%20products.ashx?App=Announcement& FileID=869491
- The milestone launch will mark a major step in the Group&rsquo s transformation journey and reinforces commitment to long-term growth
- The Biotech B-III skincare series is designed to harness the regenerative properties of nature by focusing on cellular rejuvenation
- Aims to establish itself as a leader in biotechnology through its breakthrough work in cellular rejuvenation
SINGAPORE, 10 December 2025 &ndash The board of directors (the &ldquo Board&rdquo ) of SDAI Limited (the &ldquo Company&rdquo or &ldquo SDAI&rdquo , and together with its subsidiaries, the &ldquo Group&rdquo ) is pleased to announce that the official launch of its proprietary skincare line, the Bluecode Biotech B-III skincare series (蓝 码 生 物 B-III 系 列 ) (&ldquo B-III Series&rdquo ), will take place on 21 December 2025. This debut marks a significant milestone in SDAI&rsquo s transformation journey as the Group advances into the fast-growing anti-aging and biotechnology sectors, underscoring its commitment to innovation and long-term growth.
The B-III Series will debut simultaneously in Singapore and China. In Singapore, the first product to be introduced is the Photoprotective Bio Facial Mist (抗 光 损 喷 雾 ). In China, three products will be launched concurrently: (i) the Apple Fruit Cell Serum (苹 果 果 实 细 胞 精 华 液 ), (ii) the Photoprotective Bio Facial Mist, and (iii) the Adenium Obesum Cell Facial Mask (沙 漠 蔷 薇 叶 细 胞 面 膜 ). The new products will be distributed primarily through established e-commerce platforms to maximise market reach and enhance consumer accessibility.
Revolutionising Plant Stem-Cell Skincare with Advanced Bioengineering
Developed by the Group&rsquo s in-house R& D team, the B-III Series is crafted to unlock the regenerative power of nature through cellular rejuvenation. Daily exposure to environmental stressors and modern lifestyle habits can disrupt the skin&rsquo s natural cell-to cell communication, leading to visible signs of aging including wrinkles, dullness, dehydration, loss of elasticity, and lingering scars.
Compounded by common skincare misconceptions and excessive treatments that weaken the skin barrier, premature aging becomes increasingly difficult to reverse. Under the Bluecode Biotech B-III brand, the Group redefines skincare by introducing a breakthrough approach that restores the skin&rsquo s internal communication pathways and activates its natural self-repair ability (&ldquo 激 发 肌 肤 细 胞 自 愈 力 &rdquo ).
Harnessing next-generation bioengineering and advanced plant stem-cell technology, the B-III Series rejuvenates the skin&rsquo s cellular network, enhancing balance, resilience, and youthful radiance from within. Instead of addressing concerns only at the surface level, B-III targets the root causes of cellular aging, empowering the skin to renew, rebuild and restore itself naturally.
https://links.sgx.com/FileOpen/SDAI%20-%20Launch%20of%20B-III%20products.ashx?App=Announcement& FileID=869491
SDAI Signs MoU with Hubei Qiai to Expand into the Mugwort Business
&bull Jointly establish a platform that expands Hubei Qiai&rsquo s mugwort products into the global market
&bull Leverage Hubei Qiai&rsquo s leadership in the mugwort industry, supported by its extensive nationwide presence across most of the counties and cities across China
&bull Capture the growing opportunities within the mugwort industry to broaden and diversify revenue streams
SINGAPORE, 9 December 2025 &ndash The board of directors (the &ldquo Board&rdquo ) of SDAI Limited (the &ldquo Company&rdquo or &ldquo SDAI&rdquo , and together with its subsidiaries, the &ldquo Group&rdquo ) is pleased to announce that the Company has signed a non-binding Memorandum of Understanding (&ldquo MoU&rdquo ) with Hubei Qiai Group Co., Ltd. (&ldquo Hubei Qiai&rdquo ) to jointly establish a platform that brings China&rsquo s mugwort (艾 草 ) to the global markets.
Founded in 2021, Hubei Qiai has swiftly established itself as a leading enterprise in China&rsquo s rapidly expanding Traditional Chinese Medicine (&ldquo TCM&rdquo ) health and wellness sector, with a strategic focus on the high-growth mugwort industry, one of the most promising segments within the China&rsquo s extensive medicinal herb supply chain. Hubei Qiai operates across the entire value chain, encompassing mugwort cultivation, processing, research and development, marketing and distribution to end consumers. With an extensive nationwide footprint covering most of China&rsquo s counties and cities, Hubei Qiai has built a robust retail network of over 13,000 outlets. Leveraging strong research and development capabilities, Hubei Qiai offers a diverse portfolio of mugwort-based products spanning, inter alia, food, medicine, daily essentials, skincare and home textiles. It has also integrated advanced technology into product innovation, transforming traditional moxibustion therapy into intelligent, electric-based solutions, enhancing efficiency, scalability and user experience.
Mugwort, a traditional herb known for its soothing and aromatic qualities, is gaining renewed popularity across the wellness, beauty and food industries. The global mugwort market is projected to grow to US$531.90 million in 2025, achieving a compound annual growth rate (CAGR) of 5.94% to reach US$798.75 million by 20321 . This steady growth underscores the industry&rsquo s strong momentum and the significant potential it offers for further expansion.
https://links.sgx.com/FileOpen/SDAI%20-%20MOU%20signing%20with%20Qiai%20press%20release.ashx?App=Announcement& FileID=869396
&bull Jointly establish a platform that expands Hubei Qiai&rsquo s mugwort products into the global market
&bull Leverage Hubei Qiai&rsquo s leadership in the mugwort industry, supported by its extensive nationwide presence across most of the counties and cities across China
&bull Capture the growing opportunities within the mugwort industry to broaden and diversify revenue streams
SINGAPORE, 9 December 2025 &ndash The board of directors (the &ldquo Board&rdquo ) of SDAI Limited (the &ldquo Company&rdquo or &ldquo SDAI&rdquo , and together with its subsidiaries, the &ldquo Group&rdquo ) is pleased to announce that the Company has signed a non-binding Memorandum of Understanding (&ldquo MoU&rdquo ) with Hubei Qiai Group Co., Ltd. (&ldquo Hubei Qiai&rdquo ) to jointly establish a platform that brings China&rsquo s mugwort (艾 草 ) to the global markets.
Founded in 2021, Hubei Qiai has swiftly established itself as a leading enterprise in China&rsquo s rapidly expanding Traditional Chinese Medicine (&ldquo TCM&rdquo ) health and wellness sector, with a strategic focus on the high-growth mugwort industry, one of the most promising segments within the China&rsquo s extensive medicinal herb supply chain. Hubei Qiai operates across the entire value chain, encompassing mugwort cultivation, processing, research and development, marketing and distribution to end consumers. With an extensive nationwide footprint covering most of China&rsquo s counties and cities, Hubei Qiai has built a robust retail network of over 13,000 outlets. Leveraging strong research and development capabilities, Hubei Qiai offers a diverse portfolio of mugwort-based products spanning, inter alia, food, medicine, daily essentials, skincare and home textiles. It has also integrated advanced technology into product innovation, transforming traditional moxibustion therapy into intelligent, electric-based solutions, enhancing efficiency, scalability and user experience.
Mugwort, a traditional herb known for its soothing and aromatic qualities, is gaining renewed popularity across the wellness, beauty and food industries. The global mugwort market is projected to grow to US$531.90 million in 2025, achieving a compound annual growth rate (CAGR) of 5.94% to reach US$798.75 million by 20321 . This steady growth underscores the industry&rsquo s strong momentum and the significant potential it offers for further expansion.
https://links.sgx.com/FileOpen/SDAI%20-%20MOU%20signing%20with%20Qiai%20press%20release.ashx?App=Announcement& FileID=869396
𝗦 𝗗 𝗔 𝗜 𝗢 𝗯 𝘁 𝗮 𝗶 𝗻 𝘀 𝗔 𝗽 𝗽 𝗿 𝗼 𝘃 𝗮 𝗹 𝗳 𝗼 𝗿 𝗶 𝘁 𝘀 𝗣 𝗿 𝗼 𝗽 𝗿 𝗶 𝗲 𝘁 𝗮 𝗿 𝘆 𝗣 𝗹 𝗮 𝗻 𝘁 𝗦 𝘁 𝗲 𝗺 𝗖 𝗲 𝗹 𝗹 𝘀 𝗦 𝗸 𝗶 𝗻 𝗰 𝗮 𝗿 𝗲 𝗟 𝗶 𝗻 𝗲 𝗳 𝗿 𝗼 𝗺 𝘁 𝗵 𝗲 𝗡 𝗮 𝘁 𝗶 𝗼 𝗻 𝗮 𝗹 𝗠 𝗲 𝗱 𝗶 𝗰 𝗮 𝗹 𝗣 𝗿 𝗼 𝗱 𝘂 𝗰 𝘁 𝘀 𝗔 𝗱 𝗺 𝗶 𝗻 𝗶 𝘀 𝘁 𝗿 𝗮 𝘁 𝗶 𝗼 𝗻 𝗼 𝗳 𝘁 𝗵 𝗲 𝗣 𝗲 𝗼 𝗽 𝗹 𝗲 &rsquo 𝘀 𝗥 𝗲 𝗽 𝘂 𝗯 𝗹 𝗶 𝗰 𝗼 𝗳 𝗖 𝗵 𝗶 𝗻 𝗮
𝗠 𝗮 𝗱 𝗮 𝗺 𝗛 𝗮 𝗼 𝗗 𝗼 𝗻 𝗴 𝘁 𝗶 𝗻 𝗴 (郝 东 亭 ), 𝗘 𝘅 𝗲 𝗰 𝘂 𝘁 𝗶 𝘃 𝗲 𝗖 𝗵 𝗮 𝗶 𝗿 𝗽 𝗲 𝗿 𝘀 𝗼 𝗻 𝗼 𝗳 𝘁 𝗵 𝗲 𝗖 𝗼 𝗺 𝗽 𝗮 𝗻 𝘆 , 𝗰 𝗼 𝗺 𝗺 𝗲 𝗻 𝘁 𝗲 𝗱 , &ldquo 𝘛 𝘩 𝘦 𝘵 𝘳 𝘢 𝘯 𝘴 𝘧 𝘰 𝘳 𝘮 𝘢 𝘵 𝘪 𝘰 𝘯 𝘫 𝘰 𝘶 𝘳 𝘯 𝘦 𝘺 𝘰 𝘧 𝘵 𝘩 𝘦 𝘊 𝘰 𝘮 𝘱 𝘢 𝘯 𝘺 𝘩 𝘢 𝘴 𝘣 𝘦 𝘦 𝘯 𝘤 𝘩 𝘢 𝘭 𝘭 𝘦 𝘯 𝘨 𝘪 𝘯 𝘨 , 𝘱 𝘢 𝘳 𝘵 𝘪 𝘤 𝘶 𝘭 𝘢 𝘳 𝘭 𝘺 𝘪 𝘯 𝘪 𝘥 𝘦 𝘯 𝘵 𝘪 𝘧 𝘺 𝘪 𝘯 𝘨 𝘴 𝘶 𝘴 𝘵 𝘢 𝘪 𝘯 𝘢 𝘣 𝘭 𝘦 𝘢 𝘯 𝘥 𝘱 𝘳 𝘰 𝘧 𝘪 𝘵 𝘢 𝘣 𝘭 𝘦 𝘣 𝘶 𝘴 𝘪 𝘯 𝘦 𝘴 𝘴 𝘰 𝘱 𝘱 𝘰 𝘳 𝘵 𝘶 𝘯 𝘪 𝘵 𝘪 𝘦 𝘴 𝘵 𝘰 𝘪 𝘯 𝘫 𝘦 𝘤 𝘵 𝘪 𝘯 𝘵 𝘰 𝘵 𝘩 𝘦 𝘎 𝘳 𝘰 𝘶 𝘱 𝘢 𝘮 𝘪 𝘥 𝘴 𝘵 𝘢 𝘤 𝘩 𝘢 𝘭 𝘭 𝘦 𝘯 𝘨 𝘪 𝘯 𝘨 𝘮 𝘢 𝘤 𝘳 𝘰 𝘦 𝘤 𝘰 𝘯 𝘰 𝘮 𝘪 𝘤 𝘦 𝘯 𝘷 𝘪 𝘳 𝘰 𝘯 𝘮 𝘦 𝘯 𝘵 . 𝘏 𝘰 𝘸 𝘦 𝘷 𝘦 𝘳 , 𝘸 𝘪 𝘵 𝘩 𝘶 𝘯 𝘸 𝘢 𝘷 𝘦 𝘳 𝘪 𝘯 𝘨 𝘥 𝘦 𝘵 𝘦 𝘳 𝘮 𝘪 𝘯 𝘢 𝘵 𝘪 𝘰 𝘯 , 𝘰 𝘶 𝘳 𝘵 𝘦 𝘢 𝘮 𝘩 𝘢 𝘴 𝘪 𝘥 𝘦 𝘯 𝘵 𝘪 𝘧 𝘪 𝘦 𝘥 𝘱 𝘳 𝘰 𝘮 𝘪 𝘴 𝘪 𝘯 𝘨 𝘨 𝘳 𝘰 𝘸 𝘵 𝘩 𝘱 𝘳 𝘰 𝘴 𝘱 𝘦 𝘤 𝘵 𝘴 𝘸 𝘪 𝘵 𝘩 𝘪 𝘯 𝘵 𝘩 𝘦 𝘣 𝘪 𝘰 𝘵 𝘦 𝘤 𝘩 𝘯 𝘰 𝘭 𝘰 𝘨 𝘺 𝘪 𝘯 𝘥 𝘶 𝘴 𝘵 𝘳 𝘺 .
𝘞 𝘦 𝘢 𝘳 𝘦 𝘵 𝘩 𝘳 𝘪 𝘭 𝘭 𝘦 𝘥 𝘵 𝘰 𝘩 𝘢 𝘷 𝘦 𝘳 𝘦 𝘤 𝘦 𝘪 𝘷 𝘦 𝘥 𝘳 𝘦 𝘨 𝘶 𝘭 𝘢 𝘵 𝘰 𝘳 𝘺 𝘢 𝘱 𝘱 𝘳 𝘰 𝘷 𝘢 𝘭 𝘵 𝘰 𝘴 𝘦 𝘭 𝘭 𝘰 𝘶 𝘳 𝘉 𝘭 𝘶 𝘦 𝘤 𝘰 𝘥 𝘦 𝘉 𝘪 𝘰 𝘵 𝘦 𝘤 𝘩 𝘉 -𝘐 𝘐 𝘐 𝘴 𝘬 𝘪 𝘯 𝘤 𝘢 𝘳 𝘦 𝘴 𝘦 𝘳 𝘪 𝘦 𝘴 𝘪 𝘯 𝘊 𝘩 𝘪 𝘯 𝘢 . 𝘛 𝘩 𝘪 𝘴 𝘳 𝘦 𝘨 𝘶 𝘭 𝘢 𝘵 𝘰 𝘳 𝘺 𝘢 𝘱 𝘱 𝘳 𝘰 𝘷 𝘢 𝘭 𝘮 𝘢 𝘳 𝘬 𝘴 𝘢 𝘬 𝘦 𝘺 𝘮 𝘪 𝘭 𝘦 𝘴 𝘵 𝘰 𝘯 𝘦 𝘪 𝘯 𝘰 𝘶 𝘳 𝘵 𝘳 𝘢 𝘯 𝘴 𝘪 𝘵 𝘪 𝘰 𝘯 𝘵 𝘰 𝘢 𝘣 𝘪 𝘰 𝘵 𝘦 𝘤 𝘩 𝘯 𝘰 𝘭 𝘰 𝘨 𝘺 -𝘥 𝘳 𝘪 𝘷 𝘦 𝘯 𝘤 𝘰 𝘮 𝘱 𝘢 𝘯 𝘺 . 𝘛 𝘩 𝘪 𝘴 𝘢 𝘱 𝘱 𝘳 𝘰 𝘷 𝘢 𝘭 𝘳 𝘦 𝘱 𝘳 𝘦 𝘴 𝘦 𝘯 𝘵 𝘴 𝘵 𝘩 𝘦 𝘧 𝘪 𝘳 𝘴 𝘵 𝘴 𝘵 𝘦 𝘱 𝘪 𝘯 𝘰 𝘶 𝘳 𝘣 𝘳 𝘰 𝘢 𝘥 𝘦 𝘳 𝘴 𝘵 𝘳 𝘢 𝘵 𝘦 𝘨 𝘺 𝘵 𝘰 𝘰 𝘧 𝘧 𝘦 𝘳 𝘤 𝘰 𝘯 𝘴 𝘶 𝘮 𝘦 𝘳 𝘴 𝘵 𝘳 𝘶 𝘭 𝘺 𝘪 𝘯 𝘯 𝘰 𝘷 𝘢 𝘵 𝘪 𝘷 𝘦 𝘴 𝘰 𝘭 𝘶 𝘵 𝘪 𝘰 𝘯 𝘴 𝘧 𝘰 𝘳 𝘩 𝘦 𝘢 𝘭 𝘵 𝘩 𝘢 𝘯 𝘥 𝘸 𝘦 𝘭 𝘭 𝘯 𝘦 𝘴 𝘴 .&rdquo
https://links.sgx.com/FileOpen/SDAI%20-%20Media%20Release.ashx?App=Announcement& FileID=844054
- Marking First Step in the Group&rsquo s Transformation into a Biotechnology Company.
- The approved Bluecode Biotech B-III series (蓝 码 生 物 B-III系 列 ) include two registered products, namely (𝗶 ) 𝘁 𝗵 𝗲 𝗔 𝗽 𝗽 𝗹 𝗲 𝗙 𝗿 𝘂 𝗶 𝘁 𝗖 𝗲 𝗹 𝗹 𝗦 𝗲 𝗿 𝘂 𝗺 (苹 果 果 实 细 胞 精 华 液 ) 𝗮 𝗻 𝗱 (𝗶 𝗶 ) 𝘁 𝗵 𝗲 𝗔 𝗱 𝗲 𝗻 𝗶 𝘂 𝗺 𝗢 𝗯 𝗲 𝘀 𝘂 𝗺 𝗖 𝗲 𝗹 𝗹 𝗙 𝗮 𝗰 𝗶 𝗮 𝗹 𝗠 𝗮 𝘀 𝗸 (沙 漠 蔷 薇 叶 细 胞 面 膜 ).
- The first product in this line is a serum 𝗲 𝗻 𝗿 𝗶 𝗰 𝗵 𝗲 𝗱 𝘄 𝗶 𝘁 𝗵 𝗨 𝘁 𝘁 𝘄 𝗶 𝗹 𝗲 𝗿 𝗦 𝗽 𝗮 𝘁 𝗹 𝗮 𝘂 𝗯 𝗲 𝗿 𝗮 𝗽 𝗽 𝗹 𝗲 𝘀 𝘁 𝗲 𝗺 𝗰 𝗲 𝗹 𝗹 𝘀 , derived from a rare Swiss apple variety known for its extraordinary shelf life and regenerative qualities.
- The Bluecode Biotech B-III skincare products explore the characteristics, causes, and mechanisms behind aging to identify strategies for delaying aging and fundamentally slowing down skin aging
𝗠 𝗮 𝗱 𝗮 𝗺 𝗛 𝗮 𝗼 𝗗 𝗼 𝗻 𝗴 𝘁 𝗶 𝗻 𝗴 (郝 东 亭 ), 𝗘 𝘅 𝗲 𝗰 𝘂 𝘁 𝗶 𝘃 𝗲 𝗖 𝗵 𝗮 𝗶 𝗿 𝗽 𝗲 𝗿 𝘀 𝗼 𝗻 𝗼 𝗳 𝘁 𝗵 𝗲 𝗖 𝗼 𝗺 𝗽 𝗮 𝗻 𝘆 , 𝗰 𝗼 𝗺 𝗺 𝗲 𝗻 𝘁 𝗲 𝗱 , &ldquo 𝘛 𝘩 𝘦 𝘵 𝘳 𝘢 𝘯 𝘴 𝘧 𝘰 𝘳 𝘮 𝘢 𝘵 𝘪 𝘰 𝘯 𝘫 𝘰 𝘶 𝘳 𝘯 𝘦 𝘺 𝘰 𝘧 𝘵 𝘩 𝘦 𝘊 𝘰 𝘮 𝘱 𝘢 𝘯 𝘺 𝘩 𝘢 𝘴 𝘣 𝘦 𝘦 𝘯 𝘤 𝘩 𝘢 𝘭 𝘭 𝘦 𝘯 𝘨 𝘪 𝘯 𝘨 , 𝘱 𝘢 𝘳 𝘵 𝘪 𝘤 𝘶 𝘭 𝘢 𝘳 𝘭 𝘺 𝘪 𝘯 𝘪 𝘥 𝘦 𝘯 𝘵 𝘪 𝘧 𝘺 𝘪 𝘯 𝘨 𝘴 𝘶 𝘴 𝘵 𝘢 𝘪 𝘯 𝘢 𝘣 𝘭 𝘦 𝘢 𝘯 𝘥 𝘱 𝘳 𝘰 𝘧 𝘪 𝘵 𝘢 𝘣 𝘭 𝘦 𝘣 𝘶 𝘴 𝘪 𝘯 𝘦 𝘴 𝘴 𝘰 𝘱 𝘱 𝘰 𝘳 𝘵 𝘶 𝘯 𝘪 𝘵 𝘪 𝘦 𝘴 𝘵 𝘰 𝘪 𝘯 𝘫 𝘦 𝘤 𝘵 𝘪 𝘯 𝘵 𝘰 𝘵 𝘩 𝘦 𝘎 𝘳 𝘰 𝘶 𝘱 𝘢 𝘮 𝘪 𝘥 𝘴 𝘵 𝘢 𝘤 𝘩 𝘢 𝘭 𝘭 𝘦 𝘯 𝘨 𝘪 𝘯 𝘨 𝘮 𝘢 𝘤 𝘳 𝘰 𝘦 𝘤 𝘰 𝘯 𝘰 𝘮 𝘪 𝘤 𝘦 𝘯 𝘷 𝘪 𝘳 𝘰 𝘯 𝘮 𝘦 𝘯 𝘵 . 𝘏 𝘰 𝘸 𝘦 𝘷 𝘦 𝘳 , 𝘸 𝘪 𝘵 𝘩 𝘶 𝘯 𝘸 𝘢 𝘷 𝘦 𝘳 𝘪 𝘯 𝘨 𝘥 𝘦 𝘵 𝘦 𝘳 𝘮 𝘪 𝘯 𝘢 𝘵 𝘪 𝘰 𝘯 , 𝘰 𝘶 𝘳 𝘵 𝘦 𝘢 𝘮 𝘩 𝘢 𝘴 𝘪 𝘥 𝘦 𝘯 𝘵 𝘪 𝘧 𝘪 𝘦 𝘥 𝘱 𝘳 𝘰 𝘮 𝘪 𝘴 𝘪 𝘯 𝘨 𝘨 𝘳 𝘰 𝘸 𝘵 𝘩 𝘱 𝘳 𝘰 𝘴 𝘱 𝘦 𝘤 𝘵 𝘴 𝘸 𝘪 𝘵 𝘩 𝘪 𝘯 𝘵 𝘩 𝘦 𝘣 𝘪 𝘰 𝘵 𝘦 𝘤 𝘩 𝘯 𝘰 𝘭 𝘰 𝘨 𝘺 𝘪 𝘯 𝘥 𝘶 𝘴 𝘵 𝘳 𝘺 .
𝘞 𝘦 𝘢 𝘳 𝘦 𝘵 𝘩 𝘳 𝘪 𝘭 𝘭 𝘦 𝘥 𝘵 𝘰 𝘩 𝘢 𝘷 𝘦 𝘳 𝘦 𝘤 𝘦 𝘪 𝘷 𝘦 𝘥 𝘳 𝘦 𝘨 𝘶 𝘭 𝘢 𝘵 𝘰 𝘳 𝘺 𝘢 𝘱 𝘱 𝘳 𝘰 𝘷 𝘢 𝘭 𝘵 𝘰 𝘴 𝘦 𝘭 𝘭 𝘰 𝘶 𝘳 𝘉 𝘭 𝘶 𝘦 𝘤 𝘰 𝘥 𝘦 𝘉 𝘪 𝘰 𝘵 𝘦 𝘤 𝘩 𝘉 -𝘐 𝘐 𝘐 𝘴 𝘬 𝘪 𝘯 𝘤 𝘢 𝘳 𝘦 𝘴 𝘦 𝘳 𝘪 𝘦 𝘴 𝘪 𝘯 𝘊 𝘩 𝘪 𝘯 𝘢 . 𝘛 𝘩 𝘪 𝘴 𝘳 𝘦 𝘨 𝘶 𝘭 𝘢 𝘵 𝘰 𝘳 𝘺 𝘢 𝘱 𝘱 𝘳 𝘰 𝘷 𝘢 𝘭 𝘮 𝘢 𝘳 𝘬 𝘴 𝘢 𝘬 𝘦 𝘺 𝘮 𝘪 𝘭 𝘦 𝘴 𝘵 𝘰 𝘯 𝘦 𝘪 𝘯 𝘰 𝘶 𝘳 𝘵 𝘳 𝘢 𝘯 𝘴 𝘪 𝘵 𝘪 𝘰 𝘯 𝘵 𝘰 𝘢 𝘣 𝘪 𝘰 𝘵 𝘦 𝘤 𝘩 𝘯 𝘰 𝘭 𝘰 𝘨 𝘺 -𝘥 𝘳 𝘪 𝘷 𝘦 𝘯 𝘤 𝘰 𝘮 𝘱 𝘢 𝘯 𝘺 . 𝘛 𝘩 𝘪 𝘴 𝘢 𝘱 𝘱 𝘳 𝘰 𝘷 𝘢 𝘭 𝘳 𝘦 𝘱 𝘳 𝘦 𝘴 𝘦 𝘯 𝘵 𝘴 𝘵 𝘩 𝘦 𝘧 𝘪 𝘳 𝘴 𝘵 𝘴 𝘵 𝘦 𝘱 𝘪 𝘯 𝘰 𝘶 𝘳 𝘣 𝘳 𝘰 𝘢 𝘥 𝘦 𝘳 𝘴 𝘵 𝘳 𝘢 𝘵 𝘦 𝘨 𝘺 𝘵 𝘰 𝘰 𝘧 𝘧 𝘦 𝘳 𝘤 𝘰 𝘯 𝘴 𝘶 𝘮 𝘦 𝘳 𝘴 𝘵 𝘳 𝘶 𝘭 𝘺 𝘪 𝘯 𝘯 𝘰 𝘷 𝘢 𝘵 𝘪 𝘷 𝘦 𝘴 𝘰 𝘭 𝘶 𝘵 𝘪 𝘰 𝘯 𝘴 𝘧 𝘰 𝘳 𝘩 𝘦 𝘢 𝘭 𝘵 𝘩 𝘢 𝘯 𝘥 𝘸 𝘦 𝘭 𝘭 𝘯 𝘦 𝘴 𝘴 .&rdquo
https://links.sgx.com/FileOpen/SDAI%20-%20Media%20Release.ashx?App=Announcement& FileID=844054